Genmab — November 2018
-
Jeg husker stigningen fra 900 i early days, og der kunne finanshusene slet ikke følge med op over 1400, men alle kom alligevel med kursmål over 1400. Nu hvor Dara ser ud til at blive backbone i mm og potentielt langt overstiger alles forestillinger så kan alle pludselig slet ikke se upside, med mindre der kommer nyt fra pipelinen.
-
" The Ash late-breakers unveiled yesterday offer some hope of a turnaround for Genmab.." also on the OS discussion we had earlier http://www.evaluate.com/vantage/articles/events/conferences/ash-2018-preview-blood-cancers-offer-biotech-chance-redemption
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
